Last mentioned: Feb 20, 2026
MHRA Suspension
The medicines regulator pauses the trial citing new concerns, halting the primary access route for patients.
MHRA Intervention
The UK medicines regulator issues a formal pause on the trial due to newly identified concerns.
Clinical Trial Launch
The UK government and NHS launch a formal clinical trial to gather long-term data on treatment outcomes.
Clinical Trial Launch
NHS England begins the formal clinical trial to gather data on the effects of puberty blockers.
NHS Routine Ban
NHS England ends the routine prescription of puberty blockers for gender dysphoria.
Cass Review Published
Final report recommends puberty blockers only be administered within a research setting due to lack of evidence.
Cass Review Published
Final report recommends that puberty blockers only be administered within a research framework.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has suspended a pivotal clinical trial investigating the use of puberty blockers for children. The pause follows the emergence of new regulatory concerns, effectively halting the primary research pathway for gender-affirming care in the UK.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has halted a major clinical trial into puberty blockers for minors following the emergence of new regulatory concerns. This suspension effectively closes the primary legal pathway for gender-distressed youth to access these treatments within the NHS framework.